phase readout
saveNCT07428018: Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib
NOT_YET_RECRUITINGupdated 1d ago
community read0 votes
Sponsor: Mario Negri Institute for Pharmacological Research. Phase: PHASE2. Conditions: Breast Cancer, HER2 + Breast Cancer, HR Positive, Neoadjuvant Therapy
view source ↗
comments(0)
5-min edit window · permanent after that